Alt
/content/dam/asset-migration/headshots/uk-doctor-headshots/UK_oncology_headshot_jason-lester.jpg

Dr Jason Lester

Dr Jason Lester
Jason
Lester
MB BS, MCRP, FRCR, Clinical Oncologist

Languages spoken

English

Expert in

Oncological management of lung cancers, mesothelioma, and urological (prostate, kidney, bladder) cancers. 

Overview

Centres

Bristol
Bristol

300 Park Avenue, Aztec West, Bristol BS32 4SY

51.541807689358095, -2.5709663094294277
/uk/our-centres/bristol
+44 (0)1454 456500
mediahawkNumber4110 mhMobile
Oxford
Oxford

Peters Way, Sandy Lane West, Oxford, OX4 6LB

51.7239071200697, -1.2145938932540707
/uk/our-centres/oxford
+44 (0)1865 237 700
mediahawkNumber3680 mhMobile

Specialises in

Lung cancer
Condition
Condition/Cancer
Condition/Cancer/Lung cancer
Genitourinary cancer
Condition
Condition/Cancer
Condition/Cancer/Genitourinary cancer
Prostate cancer
Condition
Condition/Cancer
Condition/Cancer/Prostate cancer

Treatments

Chemotherapy
Service
Service/Cancer
Service/Cancer/Medical oncology
Service/Cancer/Medical oncology/Chemotherapy
External beam radiotherapy
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/External beam radiotherapy
Genetic genomic testing
Service
Service/Cancer
Service/Cancer/Pathology tests and procedures
Service/Cancer/Pathology tests and procedures/Genetic testing
Image guided radiotherapy
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Image-guided radiotherapy
Immunotherapy
Service
Service/Cancer
Service/Cancer/Medical oncology
Service/Cancer/Medical oncology/Immunotherapy
Intensity modulated radiotherapy
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Intensity modulated radiotherapy
Palliative radiotherapy
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Palliative radiotherapy
Radiotherapy
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Radiotherapy
MR linac
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/MR Linac
Stereotactic ablative radiotherapy
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Stereotactic ablative radiotherapy
Surface guided radiotherapy
Service
Service/Cancer
Service/Cancer/Radiotherapy
Service/Cancer/Radiotherapy/Surface-guided radiotherapy

I qualified from United Medical and Dental Schools of Guy’s & St Thomas’s in 1993, completing general medical training in London and the South East of England. I was appointed as a Consultant Oncologist in 2003, having completed oncology training in Wales.

My special interests are the oncological management of lung cancers, mesothelioma, and urological (prostate, kidney, bladder) cancers.

I have clinical experience in using a wide range of radiotherapy treatments, including MR Linac radiotherapy, brachytherapy, stereotactic radiotherapy, and proton beam therapy, as well as more conventional conformal radiotherapy (IMRT, VMAT).

My systemic therapy experience includes the use of chemotherapy, hormone therapy, immunotherapy, radioisotopes, and targeted treatments.

There are a bewildering variety of treatments for cancer and deciding on the right therapy approach for an individual is vital. I use cancer genomic analysis where appropriate to tailor a bespoke treatment plan for people under my care.

I aim to provide advice and treatment that is comprehensive, understandable, and based on the latest research.

I have clinics in South Wales as well as Bristol and Oxford and am happy to offer remote consultations.

Expertise and interests

Interests

  • Thoracic cancers (lung, mesothelioma)
  • Urological cancers (prostate, bladder, kidney)

Professional association

  • Mesothelioma research Network member
  • UK Lung Cancer Consortium committee member
  • NCRI Advanced Diseases Subgroup
  • Fellow of the Royal College of Radiologists
  • Royal College of Physicians

Accomplishments

Awards

  • Cancer Research UK: £56,000 for the I-START trial – a dose escalation study in locally advanced NSCLC
  • June Hancock Mesothelioma Fund: £100,000 for the SKOPOS trial – A vaccine trial in mesothelioma

Publications

  • Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. CONFIRM trial investigators. Lancet Oncol. 2021 Nov; 22(11): 1530–1540
  • Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. EClinicalMedicine. 2022 May 19;48:101432
  • Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017 Apr 26;545(7655):446-451.
  • Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018 Dec 1;392(10162):2353-2366.
  • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017 Jul 27;377(4):338-351.